Bioxcel Therapeutics Stock Fundamentals
| BTAI Stock | USD 1.37 0.06 4.58% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess BioXcel Therapeutics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BioXcel Therapeutics Company Current Valuation Analysis
BioXcel Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioXcel Therapeutics Current Valuation | 83.16 M |
Most of BioXcel Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioXcel Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioXcel Therapeutics has a Current Valuation of 83.16 M. This is 99.42% lower than that of the Biotechnology sector and 98.21% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.5% higher than that of the company.
BioXcel Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioXcel Therapeutics's current stock value. Our valuation model uses many indicators to compare BioXcel Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioXcel Therapeutics competition to find correlations between indicators driving BioXcel Therapeutics's intrinsic value. More Info.BioXcel Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioXcel Therapeutics' earnings, one of the primary drivers of an investment's value.BioXcel Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioXcel Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics of similar companies.BioXcel Therapeutics is currently under evaluation in current valuation category among its peers.
BioXcel Fundamentals
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (60.11) % | ||||
| Current Valuation | 83.16 M | ||||
| Shares Outstanding | 6.06 M | ||||
| Shares Owned By Insiders | 9.09 % | ||||
| Shares Owned By Institutions | 11.03 % | ||||
| Number Of Shares Shorted | 352.19 K | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 4.48 X | ||||
| Revenue | 2.27 M | ||||
| Gross Profit | (225 K) | ||||
| EBITDA | (44.16 M) | ||||
| Net Income | (59.6 M) | ||||
| Cash And Equivalents | 233.45 M | ||||
| Cash Per Share | 8.33 X | ||||
| Total Debt | 102.95 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 12.25 X | ||||
| Book Value Per Share | (16.49) X | ||||
| Cash Flow From Operations | (72.03 M) | ||||
| Short Ratio | 0.96 X | ||||
| Earnings Per Share | (11.12) X | ||||
| Price To Earnings To Growth | (0.01) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.043 | ||||
| Market Capitalization | 8.3 M | ||||
| Total Asset | 38.34 M | ||||
| Retained Earnings | (650.2 M) | ||||
| Working Capital | 15.16 M | ||||
| Current Asset | 609.37 K | ||||
| Current Liabilities | 1.67 M | ||||
| Net Asset | 38.34 M |
About BioXcel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioXcel Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Bioxcel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out BioXcel Therapeutics Piotroski F Score and BioXcel Therapeutics Altman Z Score analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.